Skip to main navigation
Skip to content
Skip to content
PDL Logo Blue Green
  • About PDL
  • Leadership
  • Investor Relations
  • About PDL
    • Management
  • Portfolio of Assets
  • Investor Relations
  • News
  • Contact

Natasha Hernday

PDL  > Investor Relations > Natasha Hernday

Natasha Hernday

Ms. Hernday joined the PDL BioPharma Board of Directors in June 2019. She serves as Senior Vice President, Corporate Development at the publicly traded biotechnology company Seattle Genetics, Inc., where she has also served as a member of the Executive Committee since January 2011.

At Seattle Genetics, Ms. Hernday built and led the business development team responsible for sourcing, evaluating and negotiating licensing deals, acquisitions and partnerships. From 1994 to 2011, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including Director, Mergers & Acquisitions and Director, Out-Partnering. Ms. Hernday received her B.A. in microbiology from the University of California at Santa Barbara and MBA from Pepperdine University.

Ms. Hernday brings the PDL BioPharma Board of Directors extensive biotechnology experience with particular expertise in corporate development and corporate strategy. She is a member of the Compensation Committee and the Nominating and Governance Committee.

Independent Director
  • Chair of the Nominating and Governance Committee
  • Member of the Compensation Committee
  • Member of the Cost Committee

    Investor Relations

    • Frequently Asked Questions (FAQ)
    • Investor Updates
    • Press Releases
    • 2020 Proxy Statement
    • Tax Information
      • Common Stock Tax Information
      • Convertible Note Tax Information
    • SEC Filings
    • Contact Information

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • RSS
    • Print
    • Share
    • Search
    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

PDL Logo White Fill

  • Terms of Use
  • Sitemap
© Copyright 2021 PDL BioPHARMA. All Rights Reserved.